The mechanisms of resistance to echinocandin class of antifungal drugs

Japanese Journal of Medical Mycology

Volumn 50, Issue 2, 2009, Pages 57-66

  Niimi, Kyoko ^a   Niimi, Masakazu ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

1,3 glucan synthase; Amino acid substitution; Candida; Candin; Echinocandin resistant region; Echr; FKS genes; Stress response

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BETA 1,3 GLUCAN; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN; PYRROLE;

AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; CELL WALL; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; FKS GENE; FUNGAL CELL; FUNGAL GENE; FUNGAL STRAIN; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN INTERACTION; REVIEW; SACCHAROMYCES CEREVISIAE; STRUCTURE ANALYSIS;

ANTIFUNGAL AGENTS; BETA-GLUCANS; CANDIDA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; GLUCOSYLTRANSFERASES;

ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; FUNGI;

EID: 66249130675     PISSN: 09164804     EISSN: None     Source Type: Journal    
DOI: 10.3314/jjmm.50.057     Document Type: Review

References (80)

1. Kurtz MB, Douglas C, Marrinan J, Nollstadt K, Onishi J, Dreikorn S, Milligan J, Mandala S, Thompson J, Balkovec JM, Bouffard FA, Dropinski JF, Hammond ML, Zambias RA, Abruzzo G, Bartizal K, McManus OB, Garcia ML: Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother 38: 2750-2757, 1994. (Pubitemid 24374431)
2. Denning DW: Echinocandins and pneumocandins - a new antifungal class with a novel mode of action. J Antimicrob Chemother 40: 611-614, 1997.
3. Hino M, Fujie A, Iwamoto T, Hori Y, Hashimoto M, Tsurumi Y, Sakamoto K, Takase S, Hashimoto S: Chemical diversity in lipopeptide antifungal antibiotics. J Ind Microbiol Biotechnol 27: 157-162, 2001. (Pubitemid 34429803)
4. Wagner C, Graninger W, Presterl E, Joukhadar C: The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 78: 161-177, 2006.
5. Kauffman CA, Carver PL: Update on echinocandin antifungals. Semin Respir Crit Care Med 29: 211-219, 2008.
6. Bachmann SP, Patterson TF, Lopez-Ribot JL: In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 40: 2228-2230, 2002.
7. Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA: Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 44: 324-326, 2006. (Pubitemid 43222217)
8. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ: In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46: 150-156, 2008.
9. Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, Lopez-Ribot JL: In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 46: 3591-3596, 2002.
10. Nishiyama Y, Uchida K, Yamaguchi H: Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J Electron Microsc (Tokyo) 51: 247-255, 2002.
11. Nishiyama Y, Hasumi Y, Ueda K, Uchida K, Yamaguchi H: Effects of micafungin on the morphology of Aspergillus fumigatus. J Electron Microsc (Tokyo) 54: 67-77, 2005.
12. Bowman JC, Hicks PS, Kurtz MB, Rosen H, Schmatz DM, Liberator PA, Douglas CM: The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 46: 3001-3012, 2002.
13. Beauvais A, Bruneau JM, Mol PC, Buitrago MJ, Legrand R, Latge JP: Glucan synthase complex of Aspergillus fumigatus. J Bacteriol 183: 2273-2279, 2001.
14. Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, Goto T, Tomishima M, Ohki H, Yamada A, Kawabata K, Takasugi H, Sakane K, Tanaka H, Matsumoto F, Kuwahara S: In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44: 57-62, 2000.
15. Garcia-Effron G, Park S, Perlin DS: Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for C. albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 53: 112-122, 2009.
16. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S: National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 53: 283-289, 2004.
17. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ: Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol 44: 3533-3538, 2006.
18. Lass-Florl C, Mayr A, Perkhofer S, Hinterberger G, Hausdorfer J, Speth C, Fille M: Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 52: 3637-3641, 2008.
19. Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M: In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 47: 1376-1381, 2003.
20. Kang MS, Cabib E: Regulation of fungal cell wall growth: a guanine nucleotide-binding, proteinaceous component required for activity of (1 - 3) --beta-D-glucan synthase. Proc Natl Acad Sci USA 83: 5808-5812, 1986.
21. Qadota H, Python CP, Inoue SB, Arisawa M, Anraku Y, Zheng Y, Watanabe T, Levin DE, Ohya Y: Identification of yeast Rho1p GTPase as a regulatory subunit of 1,3-beta-glucan synthase. Science 272: 279-281, 1996. (Pubitemid 26119143)
22. Mio T, Adachi-Shimizu M, Tachibana Y, Tabuchi H, Inoue SB, Yabe T, Yamada-Okabe T, Arisawa M, Watanabe T, Yamada-Okabe H: Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1,3-glucan synthesis. J Bacteriol 179: 4096-4105, 1997.
23. Ohyama T, Miyakoshi S, Isono F: FKS1 mutations responsible for selective resistance of Saccharomyces cerevisiae to the novel 1,3-beta-glucan synthase inhibitor arborcandin C. Antimicrob Agents Chemother 48: 319-322, 2004.
24. Mazur P, Morin N, Baginsky W, el-Sherbeini M, Clemas JA, Nielsen JB, Foor F: Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol Cell Biol 15: 5671-5681, 1995.
25. Ishihara S, Hirata A, Nogami S, Beauvais A, Latge JP, Ohya Y: Homologous subunits of 1,3-beta-glucan synthase are important for spore wall assembly in Saccharomyces cerevisiae. Eukaryot Cell 6: 143-156, 2007.
26. Douglas CM, D'Ippolito JA, Shei GJ, Meinz M, Onishi J, Marrinan JA, Li W, Abruzzo GK, Flattery A, Bartizal K, Mitchell A, Kurtz MB: Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 41: 2471-2479, 1997.
27. Thompson JR, Douglas CM, Li W, Jue CK, Pramanik B, Yuan X, Rude TH, Toffaletti DL, Perfect JR, Kurtz M: A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function. J Bacteriol 181: 444-453, 1999.
28. Ha YS, Covert SF, Momany M: FsFKS1, the 1,3-beta-glucan synthase from the caspofungin-resistant fungus Fusarium solani. Eukaryot Cell 5: 1036-1042, 2006.
29. Sawistowska-Schroder ET, Kerridge D, Perry H: Echinocandin inhibition of 1,3-beta-D-glucan synthase from Candida albicans. FEBS Lett 173: 134-138, 1984.
30. Hatano K, Morishita Y, Nakai T, Ikeda F: Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo) 55: 219-222, 2002.
31. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS: Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 57: 705-708, 2006.
32. Baixench MT, Aoun N, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S, Ramires S, Piketty C, Dannaoui E: Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 59: 1076-1083, 2007.
33. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS: Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 52: 2263-2265, 2008.
34. Miller CD, Lomaestro BW, Park S, Perlin DS: Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26: 877-880, 2006.
35. Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, Li W, Vyas V, Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M, Teppler H, Douglas CM, Perlin DS: Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 49: 3264-3273, 2005. (Pubitemid 41060570)
36. Katiyar S, Pfaller M, Edlind T: Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 50: 2892-2894, 2006.
37. Thompson GR, 3rd, Wiederhold NP, Vallor AC, Villareal NC, Lewis JS, 2nd, Patterson TF: Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 52: 3783-3785, 2008.
38. Desnos-Ollivier M, Bretagne S, Raoux D, Hoinard D, Dromer F, Dannaoui E: Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother 52: 3092-3098, 2008.
39. Douglas CM, Marrinan JA, Li W, Kurtz MB: A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase. J Bacteriol 176: 5686-5696, 1994.
40. Kurtz MB, Abruzzo G, Flattery A, Bartizal K, Marrinan JA, Li W, Milligan J, Nollstadt K, Douglas CM: Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun 64: 3244-3251, 1996.
41. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS: A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 52: 2305-2312, 2008.
42. Perlin DS: Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 10: 121-130, 2007. (Pubitemid 47031054)
43. Rocha EM, Garcia-Effron G, Park S, Perlin DS: A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 51: 4174-4176, 2007.
44. Arendrup MC, Perkhofer S, Howard SJ, Garcia-Effron G, Vishukumar A, Perlin D, Lass-Florl C: Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother 52: 3504-3511, 2008.
45. Lesage G, Sdicu AM, Menard P, Shapiro J, Hussein S, Bussey H: Analysis of beta-1,3-glucan assembly in Saccharomyces cerevisiae using a synthetic interaction network and altered sensitivity to caspofungin. Genetics 167: 35-49, 2004.
46. Reinoso-Martin C, Schuller C, Schuetzer-Muehlbauer M, Kuchler K: The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling. Eukaryot Cell 2: 1200-1210, 2003. (Pubitemid 38047229)
47. Liu TT, Lee RE, Barker KS, Wei L, Homayouni R, Rogers PD: Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother 49: 2226-2236, 2005. (Pubitemid 40734449)
48. Levin DE: Cell wall integrity signaling in Saccharomyces cerevisiae. Microbiol Mol Biol Rev 69: 262-291, 2005.
49. Bruno VM, Kalachikov S, Subaran R, Nobile CJ, Kyratsous C, Mitchell AP: Control of the C. albicans cell wall damage response by transcriptional regulator Cas5. PLoS Pathog 2: 204-210, 2006.
50. Rauceo JM, Blankenship JR, Fanning S, Hamaker JJ, Deneault JS, Smith FJ, Nantel A, Mitchell AP: Regulation of the Candida albicans cell wall damage response by transcription factor Sko1 and PAS kinase Psk1. Mol Biol Cell 19: 2741-2751, 2008.
51. Sanglard D, Ischer F, Marchetti O, Entenza J, Bille J: Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol Microbiol 48: 959-976, 2003.
52. Cannon RD, Lamping E, Holmes AR, Niimi K, Tanabe K, Niimi M, Monk BC: Candida albicans drug resistance another way to cope with stress. Microbiology 153: 3211-3217, 2007.
53. Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow NA: Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog 4: 1-12, 2008.
54. Steinbach WJ, Cramer RA, Jr., Perfect BZ, Henn C, Nielsen K, Heitman J, Perfect JR: Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob Agents Chemother 51: 2979-2981, 2007.
55. Kontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS: Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 51: 313-316, 2003. (Pubitemid 36231150)
56. Cowen LE, Singh SD, Kohler JR, Collins C, Zaas AK, Schell WA, Aziz H, Mylonakis E, Perfect JR, Whitesell L, Lindquist S: Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci USA 106: 2818-2823, 2009.
57. Hodgetts S, Nooney L, Al-Akeel R, Curry A, Awad S, Matthews R, Burnie J: Efungumab and caspofungin: pre-clinical data supporting synergy. J Antimicrob Chemother 61: 1132-1139, 2008.
58. Stevens DA, White TC, Perlin DS, Selitrennikoff CP: Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 51: 173-178, 2005.
59. Wiederhold NP: Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect. Curr Opin Infect Dis 20: 574-578, 2007.
60. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H: Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 50: 3160-3161, 2006.
61. 2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol Microbiol 63: 1399-1413, 2007.
62. Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE: Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 49: 5146-5148, 2005.
63. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP: Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin- specific and candida species-related differences. Antimicrob Agents Chemother 51: 2257-2259, 2007.
64. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J: Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39: 2378-2386, 1995.
65. Maebashi K, Niimi M, Kudoh M, Fischer FJ, Makimura K, Niimi K, Piper RJ, Uchida K, Arisawa M, Cannon RD, Yamaguchi H: Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients. J Antimicrob Chemother 47: 527-536, 2001.
66. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, Tanabe K, Niimi M, Goffeau A, Monk BC: Efflux-mediated fungal drug resistance. Clin Rev Microbiol (In press)
67. Schuetzer-Muehlbauer M, Willinger B, Krapf G, Enzinger S, Presterl E, Kuchler K: The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol 48: 225-235, 2003.
68. Niimi K, Maki K, Ikeda F, Holmes AR, Lamping E, Niimi M, Monk BC, Cannon RD: Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob Agents Chemother 50: 1148-1155, 2006.
69. Silver PM, Oliver BG, White TC: Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance. Med Mycol 46: 231-239, 2008.
70. Richards TS, Oliver BG, White TC: Micafungin activity against Candida albicans with diverse azole resistance phenotypes. J Antimicrob Chemother 62: 349-355, 2008.
71. Smriti, Krishnamurthy S, Dixit BL, Gupta CM, Milewski S, Prasad R: ABC transporters Cdr1p, Cdr2p and Cdr3p of a human pathogen Candida albicans are general phospholipid translocators. Yeast 19: 303-318, 2002.
72. Hernandez S, Lopez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR: Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 48: 1382-1383, 2004. (Pubitemid 38405501)
73. Moudgal V, Little T, Boikov D, Vazquez JA: Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49: 767-769, 2005.
74. Maligie MA, Selitrennikoff CP: Cryptococcus neoformans resistance to echinocandins: (1,3) beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother 49: 2851-2856, 2005.
75. Del Poeta M, Cruz MC, Cardenas ME, Perfect JR, Heitman J: Synergistic antifungal activities of bafilomycin A (1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother 44: 739-746, 2000. (Pubitemid 30117971)
76. Steinbach WJ, Reedy JL, Cramer RA. Jr., Perfect JR, Heitman J: Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 5: 418-430, 2007.
77. Balashov SV, Park S, Perlin DS: Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 50: 2058-2063, 2006. (Pubitemid 43807526)
78. Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS: Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother 52: 4181-4183, 2008.